CN104520300B - 作为激酶抑制剂的咪唑并[1,2-b]哒嗪衍生物 - Google Patents

作为激酶抑制剂的咪唑并[1,2-b]哒嗪衍生物 Download PDF

Info

Publication number
CN104520300B
CN104520300B CN201380041498.XA CN201380041498A CN104520300B CN 104520300 B CN104520300 B CN 104520300B CN 201380041498 A CN201380041498 A CN 201380041498A CN 104520300 B CN104520300 B CN 104520300B
Authority
CN
China
Prior art keywords
compound
amino
imidazo
phenyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380041498.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN104520300A (zh
Inventor
武田泰幸
吉川谦次
神子岛佳子
山本裕子
田中亮
田中亮一
富永裕
富永裕一
木我真基
浜田义人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of CN104520300A publication Critical patent/CN104520300A/zh
Application granted granted Critical
Publication of CN104520300B publication Critical patent/CN104520300B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201380041498.XA 2012-06-04 2013-06-03 作为激酶抑制剂的咪唑并[1,2-b]哒嗪衍生物 Active CN104520300B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012-127079 2012-06-04
JP2012127079 2012-06-04
PCT/JP2013/065328 WO2013183578A1 (ja) 2012-06-04 2013-06-03 キナーゼ阻害剤としてのイミダゾ[１，２－ｂ]ピリダジン誘導体

Publications (2)

Publication Number Publication Date
CN104520300A CN104520300A (zh) 2015-04-15
CN104520300B true CN104520300B (zh) 2016-12-21

Family

ID=49711970

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380041498.XA Active CN104520300B (zh) 2012-06-04 2013-06-03 作为激酶抑制剂的咪唑并[1,2-b]哒嗪衍生物

Country Status (32)

Country Link
US (2) US9187489B2 (enExample)
EP (1) EP2857404B1 (enExample)
JP (1) JP5814467B2 (enExample)
KR (1) KR101781255B1 (enExample)
CN (1) CN104520300B (enExample)
AU (1) AU2013272701B2 (enExample)
BR (1) BR112014029851B1 (enExample)
CA (1) CA2874819C (enExample)
CO (1) CO7160119A2 (enExample)
CY (1) CY1119607T1 (enExample)
DK (1) DK2857404T3 (enExample)
ES (1) ES2648228T3 (enExample)
HR (1) HRP20171724T1 (enExample)
HU (1) HUE037221T2 (enExample)
IL (1) IL236075A (enExample)
IN (1) IN2014MN02497A (enExample)
LT (1) LT2857404T (enExample)
MX (1) MX357021B (enExample)
MY (1) MY170326A (enExample)
NO (1) NO2857404T3 (enExample)
NZ (1) NZ702574A (enExample)
PH (1) PH12014502721A1 (enExample)
PL (1) PL2857404T3 (enExample)
PT (1) PT2857404T (enExample)
RS (1) RS56625B1 (enExample)
RU (1) RU2635917C2 (enExample)
SG (1) SG11201408052WA (enExample)
SI (1) SI2857404T1 (enExample)
SM (1) SMT201700539T1 (enExample)
TW (1) TWI585088B (enExample)
WO (1) WO2013183578A1 (enExample)
ZA (1) ZA201408843B (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53350B (sr) 2008-09-22 2014-10-31 Array Biopharma, Inc. Supstituisana jedinjenja imidazo[1,2-b]piridazina kao inhibitori trk kinaze
PT2725028T (pt) 2008-10-22 2016-08-31 Array Biopharma Inc Compostos de pirazolo[1,5-]pirimidina substituídos como intermediários na síntese de inibidores de cinase trk
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
HUE044025T2 (hu) 2010-05-20 2019-09-30 Array Biopharma Inc Makrociklusos vegyületek mint TRK-kináz inhibitorok
CN104470918A (zh) 2012-05-30 2015-03-25 日本新药株式会社 芳香族杂环衍生物及医药
BR112016022105B1 (pt) 2014-03-27 2023-01-31 Janssen Pharmaceutica Nv Derivados de 4,5,6,7-tetra-hidro-pirazolo[1,5- a]pirazina substituídos e derivados de 5,6,7,8-tetrahidro-4h-pirazolo[1,5-a][1,4]diazepina como inibidores do ros1 e composição farmacêutica que os compreende
BR112016021507B1 (pt) * 2014-03-27 2022-10-18 Janssen Pharmaceutica Nv Derivados de 4,5,6,7-tetra-hidro-pirazolo[1,5-a]pirimidina substituídos e derivados de 2,3-dihidro-1himidazo[1,2-b]pirazol como inibidores do ros1 e composição farmacêutica que os compreende
BR112016024672A2 (pt) * 2014-04-25 2021-02-02 Exelixis, Inc método para o tratamento de adenocarcinoma de pulmão
FI3699181T3 (fi) 2014-11-16 2023-03-28 Array Biopharma Inc Kiteinen muoto (s)-n-(5-((r)-2-(2,5-diluorifenyyli)-pyrrolidin-1-yyli)-pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidivetyysulfaatista
MX2017015461A (es) 2015-06-01 2018-08-15 Loxo Oncology Inc Métodos para diagnosticar y tratar el cáncer.
MX379846B (es) 2015-06-18 2025-03-11 89Bio Ltd Derivados de 4-bencil y 4-benzoil piperidina sustituidos.
AU2016280255A1 (en) 2015-06-18 2018-02-08 Cephalon, Inc. 1, 4-substituted piperidine derivatives
PL3322706T3 (pl) 2015-07-16 2021-07-19 Array Biopharma, Inc. Podstawione związki pirazolo[1,5-a]pirydynowe jako inhibitory kinazy ret
EP3368039A1 (en) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Point mutations in trk inhibitor-resistant cancer and methods relating to the same
CN106854174A (zh) * 2015-12-08 2017-06-16 湖南华腾制药有限公司 一种4位取代哌啶衍生物的制备方法
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
CA3019661A1 (en) 2016-04-04 2017-10-12 Loxo Oncology, Inc. Methods of treating pediatric cancers
RS65987B1 (sr) 2016-04-04 2024-10-31 Loxo Oncology Inc Tečne formulacije (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirolidin-1-il)-pirazolo[1,5-]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
EP3800189B1 (en) 2016-05-18 2023-06-28 Loxo Oncology, Inc. Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
CN107400082A (zh) * 2016-05-19 2017-11-28 湖南华腾制药有限公司 一种取代哌啶衍生物的制备方法
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
US11028091B2 (en) * 2017-03-14 2021-06-08 Daiichi Sankyo Company, Limited Method for producing 3, 6-disubstituted imidazo[1, 2-b]pyridazine derivative
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
US20190247398A1 (en) 2017-10-26 2019-08-15 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
CN109748902B (zh) * 2017-11-02 2020-11-06 杭州科巢生物科技有限公司 一种盐酸安罗替尼的制备方法
JP7041265B2 (ja) * 2017-11-29 2022-03-23 ソウル大学校産学協力団 抗－ｒｏｓ１抗体およびその用途
CN108129288B (zh) * 2017-12-27 2021-01-22 上海毕得医药科技股份有限公司 一种反式-3-羟基环丁基甲酸的合成方法
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
WO2019191659A1 (en) 2018-03-29 2019-10-03 Loxo Oncology, Inc. Treatment of trk-associated cancers
EP3827009A4 (en) 2018-07-24 2022-04-27 Taiho Pharmaceutical Co., Ltd. HETEROBICYCLIC COMPOUNDS TO INHIBIT SHP2 ACTIVITY
CN117281803A (zh) 2018-07-31 2023-12-26 罗索肿瘤学公司 喷雾干燥的分散体和制剂
WO2020055672A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
JP2022515197A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド がんを治療するためのｆｇｆｒ阻害剤としての７－（（３，５－ジメトキシフェニル）アミノ）キノキサリン誘導体
CN113543852A (zh) * 2019-03-06 2021-10-22 第一三共株式会社 吡咯并吡唑衍生物
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
AU2020270303B2 (en) * 2019-05-08 2023-09-07 Tyk Medicines, Inc. Compound used as kinase inhibitor and application thereof
GB201911928D0 (en) 2019-08-20 2019-10-02 Otsuka Pharma Co Ltd Pharmaceutical compounds
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202200589A (zh) * 2020-05-28 2022-01-01 瑞士商諾華公司 Ｍｌｌ１抑制劑及抗癌劑
CN114957259A (zh) * 2021-02-25 2022-08-30 南京明德新药研发有限公司 氰基取代的芳香双环类化合物及其应用
US20240309007A1 (en) * 2021-07-01 2024-09-19 Anheart Therapeutics (Hangzhou) Co., Ltd. Crystalline forms of 3-{4-[(2r)-2-aminopropoxy]phenyl}-n-[(1r)- 1-(3-fluorophenyl) ethyl]imidazo[1,2-b]pyridazin-6-amine and salts thereof
CN119546609A (zh) * 2022-05-18 2025-02-28 葆元生物医药科技(杭州)有限公司 用于制备3,6-二取代-咪唑并[1,2-b]哒嗪化合物的方法
CN114989176B (zh) * 2022-07-08 2024-08-27 深圳市新樾生物科技有限公司 咪唑并哒嗪类衍生物及其应用
CN115197115B (zh) * 2022-08-25 2024-11-08 成都金博汇康医药科技有限公司 一种手性5-氧代吡咯烷-3-甲酸的制备方法与应用
CN117659043A (zh) 2022-09-07 2024-03-08 苏州朗睿生物医药有限公司 一种大环咪唑并[1,2-b]哒嗪衍生物及其制备方法和用途
CN117659020A (zh) * 2022-09-07 2024-03-08 苏州朗睿生物医药有限公司 一种咪唑并[1,2-b]哒嗪衍生物及其制备方法和用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008072682A1 (ja) * 2006-12-15 2008-06-19 Daiichi Sankyo Company, Limited イミダゾ［１，２－ｂ］ピリダジン誘導体
US20080167314A1 (en) * 2004-12-28 2008-07-10 Osamu Uchikawa Condensed Imidazole Compound And Use Thereof
CN101522682A (zh) * 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
JP2009227599A (ja) * 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
WO2011049332A2 (en) * 2009-10-22 2011-04-28 Korea Institute Of Science And Technology 2,7-substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors
CN102056927A (zh) * 2008-05-13 2011-05-11 Irm责任有限公司 作为激酶抑制剂的稠合含氮杂环及其组合物
CN102224153A (zh) * 2008-09-22 2011-10-19 阵列生物制药公司 作为trk激酶抑制剂的取代的咪唑并[1,2-b]哒嗪化合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
EP1317446A1 (en) 2000-09-01 2003-06-11 Glaxo Group Limited Oxindole derivatives
WO2002020479A1 (en) 2000-09-01 2002-03-14 Glaxo Group Limited Substituted oxindole derivatives as tyrosine kinase inhibitors
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
US20090227648A1 (en) 2004-04-21 2009-09-10 Astrazeneca Ab Pyrazole derivatives useful for the treatment of cancer
DK2383268T3 (en) 2005-02-04 2015-09-14 Astrazeneca Ab PYRAZOLYLAMINOPYRIDINDERIVATER useful as kinase inhibitors
AU2006215386B2 (en) 2005-02-16 2009-06-11 Astrazeneca Ab Chemical compounds
AU2006215394B2 (en) 2005-02-16 2009-10-08 Astrazeneca Ab Chemical compounds
US20100216798A1 (en) 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors
US7776878B2 (en) * 2005-08-01 2010-08-17 Hoffmann-La Roche Inc. Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE102006029447A1 (de) 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel
CN101600718B (zh) 2006-11-06 2013-07-03 特雷罗药物股份有限公司 咪唑并[1,2-b]哒嗪和吡唑并[1,5-a]嘧啶衍生物及其作为蛋白激酶抑制剂的用途
JPWO2012005299A1 (ja) 2010-07-07 2013-09-05 日本新薬株式会社 Ｒｏｓチロシンキナーゼ阻害剤
WO2012125667A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080167314A1 (en) * 2004-12-28 2008-07-10 Osamu Uchikawa Condensed Imidazole Compound And Use Thereof
CN101522682A (zh) * 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
WO2008072682A1 (ja) * 2006-12-15 2008-06-19 Daiichi Sankyo Company, Limited イミダゾ［１，２－ｂ］ピリダジン誘導体
JP2009227599A (ja) * 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
CN102056927A (zh) * 2008-05-13 2011-05-11 Irm责任有限公司 作为激酶抑制剂的稠合含氮杂环及其组合物
CN102224153A (zh) * 2008-09-22 2011-10-19 阵列生物制药公司 作为trk激酶抑制剂的取代的咪唑并[1,2-b]哒嗪化合物
WO2011049332A2 (en) * 2009-10-22 2011-04-28 Korea Institute Of Science And Technology 2,7-substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors

Also Published As

Publication number Publication date
ES2648228T3 (es) 2017-12-29
CA2874819C (en) 2017-06-20
DK2857404T3 (en) 2017-12-04
MY170326A (en) 2019-07-17
KR20150014942A (ko) 2015-02-09
PH12014502721B1 (en) 2015-02-02
SI2857404T1 (sl) 2017-11-30
IL236075A0 (en) 2015-02-01
HUE037221T2 (hu) 2018-08-28
TWI585088B (zh) 2017-06-01
BR112014029851A2 (pt) 2017-06-27
CN104520300A (zh) 2015-04-15
BR112014029851B1 (pt) 2023-01-03
CY1119607T1 (el) 2018-04-04
CA2874819A1 (en) 2013-12-12
MX357021B (es) 2018-06-25
EP2857404A1 (en) 2015-04-08
IL236075A (en) 2017-10-31
NO2857404T3 (enExample) 2018-01-20
US20150051190A1 (en) 2015-02-19
SG11201408052WA (en) 2015-01-29
EP2857404A4 (en) 2016-01-20
SMT201700539T1 (it) 2018-01-11
EP2857404B1 (en) 2017-08-23
US20160046639A1 (en) 2016-02-18
JP5814467B2 (ja) 2015-11-17
CO7160119A2 (es) 2015-01-15
PT2857404T (pt) 2017-11-23
PL2857404T3 (pl) 2018-04-30
JPWO2013183578A1 (ja) 2016-01-28
HRP20171724T1 (hr) 2018-01-12
US9187489B2 (en) 2015-11-17
AU2013272701A1 (en) 2015-01-15
US9751887B2 (en) 2017-09-05
PH12014502721A1 (en) 2015-02-02
RS56625B1 (sr) 2018-03-30
TW201400486A (zh) 2014-01-01
AU2013272701A2 (en) 2015-01-22
ZA201408843B (en) 2016-01-27
RU2014153627A (ru) 2016-08-10
NZ702574A (en) 2016-07-29
MX2014014803A (es) 2015-02-12
HK1207374A1 (en) 2016-01-29
WO2013183578A1 (ja) 2013-12-12
AU2013272701B2 (en) 2017-12-21
RU2635917C2 (ru) 2017-11-17
LT2857404T (lt) 2017-11-10
KR101781255B1 (ko) 2017-09-22
IN2014MN02497A (enExample) 2015-07-17

Similar Documents

Publication Publication Date Title
CN104520300B (zh) 作为激酶抑制剂的咪唑并[1,2-b]哒嗪衍生物
JP7033764B2 (ja) Ｃｄｋ阻害剤としての置換型ヘテロシクリル誘導体
JP5639261B2 (ja) ピラゾリルキノキサリンキナーゼ阻害剤
JP7254094B2 (ja) Ｐｒｍｔ５阻害剤としての置換イミダゾリジン－２－オン誘導体
JP7549597B2 (ja) Ｅｅｄおよびｐｒｃ２調節物質としての大環状アゾロピリジン誘導体
MX2007009842A (es) Compuestos quimicos.
CN115315422B (zh) 酰胺类化合物及其用途
EP3694331A1 (en) Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
EP4141003A1 (en) Pyrazolo[1,5-a]pyridine derivative, preparation method therefor, and composition and use thereof
HK1207374B (en) Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
HK40082804A (en) Amide compounds and uses thereof
HK40082804B (zh) 酰胺类化合物及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant